BMS-852927 (XL041)

BMS-852927 (XL041) is a small-molecule modulator of the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. Exelixis discovered BMS-852927 during a collaboration with Bristol-Myers Squibb Company aimed at optimizing and characterizing modulators of LXRs that would promote reverse cholesterol transport without raising triglycerides. A phase 1 clinical trial evaluating the compound’s safety is ongoing.